NASDAQ:ELDN - Nasdaq - US28617K1016 - Common Stock - Currency: USD
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results...
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eledon Pharma (NASDAQ:ELDN) just reported results for the second quarter of 202...
ELDN stock results show that Eledon Pharma missed analyst estimates for earnings per share the second quarter of 2024.
ELDN stock results show that Eledon Pharma beat analyst estimates for earnings per share the first quarter of 2024.
Eledon Announces Tegoprubart Use as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human...
Eledon Pharmaceuticals to Participate in Guggenheim SMID Cap Biotech Conference...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eledon Pharma (NASDAQ:ELDN) just reported results for the first quarter of 2024...
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook...
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results...
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants...
Eledon Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of Regimen Following Islet Transplantation...
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference...
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplants...
Enrollment Completed Four Months Ahead of Schedule
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results...
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection...
80 Participants (Two-thirds of Projected Recruitment) Enrolled
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism...
You don’t want to overlook these three penny stocks filled to the brim with the potential to make huge leaps in their respective markets.
Although the very idea of millionaire-maker penny stocks implies incredibly high risks, if all cylinders fire, these companies could fly.
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation...
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results...
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at ATC 2024...